BACKGROUND: Differences in disease-modifying therapy (DMT) prescribing patterns between different groups of neurologists have not been explored. HYPOTHESIS: MS-specialist neurologists use a broader range of DMTs in contrast to generalist neurologists who preferentially prescribe Avonex. METHODS: Ontario neurologist demographic and geographical characteristics were linked to 2009 DMT prescription data. Lorenz curves and Gini coefficients were constructed to examine prescribing patterns; separating neurologist characteristics dichotomously and separating Avonex from the other DMTs. Gini Coefficients were compared using jack-knife statistical techniques to derive 95% confidence intervals. RESULTS: Prescriptions are highly concentrated...
BACKGROUND: Effectiveness of cladribine tablets, an oral disease-modifying treatment (DMT) for multi...
OBJECTIVES: This study had two aims: to measure the prevalence of long-term prescribing of high dose...
Background: Teriflunomide (TERI) and dimethyl fumarate (DMF) are licensed as first-line disease-modi...
BACKGROUND: Differences in disease-modifying therapy (DMT) prescribing patterns between different g...
ObjectiveTo examine neurotologists' 2013 to 2016 Medicare Part-D data and evaluate commonly prescrib...
Importance: The prescription of generic (non-proprietary) compared to brand-name drugs is increasing...
Jinender Kumar,1 M Janelle Cambron-Mellott,2 Tom Tencer,1 Oliver Will,2 deMauri S Mackie,2 Kathleen ...
Introduction: The management of multiple sclerosis (MS) has become more complicated after the introd...
AIMS: To examine the association between socioeconomic status (SES) and disease-modifying therapy (D...
Background The choice between disease-modifying drugs (DMDs) for the treatment of multiple sclerosis...
grantor: University of Toronto'Purpose'. Disease-modifying drugs (DMDS) are a recent break...
none6Background: Current treatment of multiple sclerosis (MS) with disease-modifying drugs (DMDs) i...
Copyright © 2014 Michael T. Halpern et al. This is an open access article distributed under the Crea...
Background: The French National Health Insurance and the Ministry of Health have introduced multiple...
Background The proportion of people with relapsing-remitting multiple sclerosis prescribed disease m...
BACKGROUND: Effectiveness of cladribine tablets, an oral disease-modifying treatment (DMT) for multi...
OBJECTIVES: This study had two aims: to measure the prevalence of long-term prescribing of high dose...
Background: Teriflunomide (TERI) and dimethyl fumarate (DMF) are licensed as first-line disease-modi...
BACKGROUND: Differences in disease-modifying therapy (DMT) prescribing patterns between different g...
ObjectiveTo examine neurotologists' 2013 to 2016 Medicare Part-D data and evaluate commonly prescrib...
Importance: The prescription of generic (non-proprietary) compared to brand-name drugs is increasing...
Jinender Kumar,1 M Janelle Cambron-Mellott,2 Tom Tencer,1 Oliver Will,2 deMauri S Mackie,2 Kathleen ...
Introduction: The management of multiple sclerosis (MS) has become more complicated after the introd...
AIMS: To examine the association between socioeconomic status (SES) and disease-modifying therapy (D...
Background The choice between disease-modifying drugs (DMDs) for the treatment of multiple sclerosis...
grantor: University of Toronto'Purpose'. Disease-modifying drugs (DMDS) are a recent break...
none6Background: Current treatment of multiple sclerosis (MS) with disease-modifying drugs (DMDs) i...
Copyright © 2014 Michael T. Halpern et al. This is an open access article distributed under the Crea...
Background: The French National Health Insurance and the Ministry of Health have introduced multiple...
Background The proportion of people with relapsing-remitting multiple sclerosis prescribed disease m...
BACKGROUND: Effectiveness of cladribine tablets, an oral disease-modifying treatment (DMT) for multi...
OBJECTIVES: This study had two aims: to measure the prevalence of long-term prescribing of high dose...
Background: Teriflunomide (TERI) and dimethyl fumarate (DMF) are licensed as first-line disease-modi...